May Health Raises $25 Million in Series B Funding to Advance Development for Ovarian Rebalancing Therapy

May Health Raises $25 Million in Series B Funding to Advance Development for Ovarian Rebalancing Therapy

Business Wire

Published

PARIS--(BUSINESS WIRE)--May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), today announced it has closed a $25 million Series B financing round, co-led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets LP. Funds will be used to support the company’s growth and advance its Ovarian Rebalancing™ therapy thr

Full Article